Pharmacological actions of novel beta-lactam and non-beta lactam compounds on major astrocytic glutamate transporters in the brain and liver of male C57BL/6 mice exposed chronically to hydrocodone Authors: Woonyen Wong, Adil Shareef Mohammed, Wayne E Childers, Magid Abou-Gharbia, Youssef Sari Published: 2026 ABSTRACT AbstractChronic exposure to opioid reduced the expression of astrocytic glutamate transporter 1 (GLT-1) and cystine/glutamate antiporter (xCT) in the mesocorticolimbic brain region and ceftriaxone, a beta-lactam antibiotic, attenuated this effect. Importantly, a novel synthetic non-antibiotic beta-lactam, MC-100093, was found effective in attenuating fentanyl and morphine overdose-induced reduction in GLT-1 expression in the nucleus accumbens (NAc) as well as attenuated fentanyl-induced liver inflammation and disruption of liver metabolites. In the present study, two novel synthetic non-antibiotic beta-lactams, MC-100093 and MC-290401, and one novel synthetic non-beta-lactam bicyclic, MC-290013, were tested in a mouse model of chronic exposure to hydrocodone with focus on GLT-1 expression as well as the transcriptional regulation of GLT-1. This study reports that MC-100093, MC-290401, and MC-290013 treatment attenuated hydrocodone-induced downregulation of GLT-1 in the NAc. MC-100093, MC-290401, and MC-290013 treatments normalized GLT-1 and xCT expression in the NAc, and this effect was associated with upregulation of NFκB in the nuclear fraction and downregulation of the expression of mTOR and IKB-α in the cytoplasmic fraction as well as upregulation of pAkt expression in the NAc. Furthermore, histological and statistical analyses revealed that MC-100093, MC-290401, and MC-290013 treatments attenuated chronic hydrocodone-induced liver inflammation (TNF-α, IL-1β, and IL-6). Finally, these GLT-1 modulators attenuated hydrocodone-induced upregulation of hepatic xCT and GLT-1. These findings suggest that these novel synthetic GLT-1 modulators may be considered as potential agents to attenuate hydrocodone-induced alterations in glutamate transporters and associated target proteins in the brain and liver.Keywords: Opioids, GLT-1, xCT, Liver, Glutamate, Inflammation Introduction Glutamate is the main excitatory neurotransmitter in the central nervous system, that is linked to other neurotransmitter signaling pathways for the regulation of synaptic plasticity [1]. Excessive glutamate concentration in the synaptic cleft can lead to neuronal death [2]. Regulation of glutamate homeostasis is of great importance. Glutamate transporter 1 (GLT-1) is a major transporter that regulates the majority of extracellular glutamate concentrations in the brain. Previous study from our laboratory demonstrated that chronic exposure to hydrocodone reduced GLT-1 expression in several reward brain regions, including the nucleus accumbens (NAc); treatment with beta-lactam, ceftriaxone, mitigated this effect [3]. Emerging evidence showed that transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) increase GLT-1 expression and reverse glutamate excitotoxicity [[4], [5], [6]]. The mammalian target of rapamycin (mTOR) is known to regulate NF-κB activation, thereby regulating GLT-1 expression [7,8]. In addition, the signaling protein, protein kinase B (Akt) is also known to promote NF-κB activation and is involved in the upregulation of GLT-1 expression [9]. Three novel synthetic compounds (MC-100093, MC-290401, and MC-290013) were synthesized to enhance glutamate transporter regulation without antibiotic activity. Treatment with the novel non-antibiotic beta-lactam compound, MC-100093, reduced ethanol intake and neuroinflammation in alcohol-preferring rats [[10], [11], [12]], attenuated cocaine relapse behavior in rats [13], and alleviated opioids- (fentanyl and morphine) induced neuroinflammation in mice [14,15]. However, the molecular mechanism underlying its effect has not been well characterized. In addition, two additional GLT-1 enhancers, MC-290401 and MC-290013, have not been previously evaluated under chronic hydrocodone exposure. Evaluating these compounds could provide an opportunity to explore their potential in modulating glutamate transport and inflammatory responses in both brain and liver affected by chronic hydrocodone exposure. Therefore, in this study, we focused on testing whether novel synthetic compounds, non-antibiotic beta-lactam compounds, MC-100093 and MC-290401, and non-beta-lactam bicyclic compound, MC-290013, could potentially alleviate dysregulation of the astrocytic glutamate transporters such as GLT-1 as well as cystine/glutamate antiporter (xCT) in the NAc of mice. This study further examined the expression of target proteins that are suggested to be involved in the modulation of GLT-1 and xCT with these novel synthetic compounds, MC-100093, MC-290401, and MC-290013. This study also explored the efficacy of MC-100093, MC-290401, and MC-290013 against the effect of chronic exposure to hydrocodone in the liver, which is an important metabolic organ that is susceptible to drug-induced toxicity. Chronic morphine exposure is the leading cause of drug-induced hepatotoxicity, which can result in acute liver failure [16]. Furthermore, fentanyl overdose impaired liver metabolites and induced inflammation, and MC-100093 treatment restored fentanyl-induced liver inflammation and certain metabolites [17]. In this study, we tested hydrocodone as an opioid drug to determine the efficacy of novel GLT-1 modulators in the brain and liver. Hydrocodone is widely used to treat chronic pain and it is metabolized by the hepatic cytochrome CYP2D6 and CYP3A4 isozymes to form hydromorphone and norhydrocodone [18]. Short-term use of hydrocodone is not generally associated with hepatotoxicity. However, little is known about the long-term effects of hydrocodone on the brain and the liver. Previous study form our laboratory reported that the beta-lactam antibiotic, ceftriaxone, significantly alleviated chronic hydrocodone-induced dysfunction in the glutamatergic system in the brain [3]. However, ceftriaxone has low oral bioavailability, CNS penetration, and the risk of bacterial resistance [19,20]. To address these limitations, this current study tested the non-antibiotic beta-lactam compounds, MC-100093 and MC-290401, as well as the non-beta-lactam compound, MC-290013, which have considerable CNS bioavailability and no antibiotic effects as compared to ceftriaxone. MC-100093 was shown to have high aqueous solubility, high stability in rodent and human liver microsomes in vitro, and the drug displayed low binding to plasma protein and low partitioning into lipid membranes [13]. In vivo pharmacokinetic studies found that MC-100093 displayed some bioavailability following oral administration [13]. In this study, we aimed to elucidate whether the non-antibiotic beta-lactams, MC-100093 and MC-290401, and the non-beta-lactam compound, MC290013, upregulate GLT-1 expression and determined the expression of target proteins as part of the mTOR-Akt-NFκB signaling cascade in key reward brain regions such as the NAc. This study focused on the NAc as a major brain region that is targeted and disrupted by most of the drugs of abuse, and this brain region receives and sends projections to different cortical and limbic brain regions, which are involved in goal directed behaviors [21]. Related to the liver, glutamate, the primary excitatory neurotransmitter, is also involved in several metabolic pathways [22], and it is essential for the synthesis of glutathione, which acts as an antioxidant in the liver and can reverse ethanol-induced liver injury [23]. GLT-1 is expressed in the liver [24], and is responsible for maintaining the majority of extracellular glutamate concentrations [25]. Thus, this study also investigated the effects of chronic hydrocodone exposure and GLT-1 enhancers on hepatic glutamate transporters and inflammation using Western blotting, Elisa, and histological analysis. These results provide a foundation for understanding how novel GLT-1 modulators may influence opioid-induced central and peripheral changes. Materials and Methods Animals Male C57BL/6 J mice (20–30 g, 8 weeks old) were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Upon arrival, all mice were acclimated for three days before performing any experiments. After acclimatization, mice were housed in standard cages at The University of Toledo with free access to food and water in a temperature-controlled vivarium (maintained at 21 °C) with an alternating 12-h light/dark cycle. All experimental procedures used in this study followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee (IACUC) at The University of Toledo, under protocol number 400155 (approved August 2, 2022). Mice were monitored daily throughout the study to ensure minimal suffering. Drugs and treatment Hydrocodone was purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in sterile saline at 1 mg/ml. MC-100093 (beta-lactam), MC-290401 (beta-lactam), and MC-290013 (non-beta lactam) were synthesized at Temple University School of Pharmacy, Moulder Center for Drug Discovery Research (Philadelphia, PA). All three compounds were synthesized as a white powder and dissolved in sterile saline at 10 mg/ml. Chemical structures of ceftriaxone, MC-100093, MC-290401, and MC-290013 are reported in Supplementary Fig. 1. Mice in the control group received an equal volume of vehicle (saline). All drugs and chemicals were injected intraperitoneally (i.p.). Study design Male mice were randomly divided into five experimental groups (n = 6 per group): 1) Saline + saline; 2) hydrocodone + saline; 3) Hydrocodone + MC-100093; 4) Hydrocodone + MC-290013; and 5) hydrocodone + MC-290401. Mice in group 1 received a daily i. p. Saline injection from Day 1 to Day 14. In group 2, mice received daily i. p. injection of hydrocodone (10 mg/kg; from Day 1 to Day 14) and saline (equal volume; from Day 7 to Day 14). In group 3, mice received daily i. p. injection of hydrocodone (10 mg/kg; from Day 1 to Day 14) and MC-100093 (100 mg/kg; from Day 7 to Day 14). In group 4, mice received daily i. p. injection of hydrocodone (10 mg/kg; from Day 1 to Day 14) and MC-290013 (100 mg/kg; from Day 7 to Day 14). In group 5, mice received daily i. p. injection of hydrocodone (10 mg/kg; from Day 1 to Day 14) and MC-290401 (100 mg/kg; from Day 7 to Day 14). The hydrocodone dose used (10 mg/kg, i. p.) was based on previous study [3], and the dose used for GLT-1 enhancers (100 mg/kg, i. p.) is based on recent studies [11,12,26]. Brain and liver tissues extraction On Day 15, all male mice were euthanized by CO2 inhalation followed by cardiac puncture for blood extraction and then rapidly decapitated with a guillotine. Although CO2 may influence certain neurobiological markers, it is an IACUC-approved method, and tissues were collected rapidly. The brains were isolated and frozen immediately on dry ice and stored at −80 °C. Nucleus accumbens (NAc) was extracted using a cryostat machine (Leica CM1950). NAc was selected using Brain Mice Atlas [27]. Liver samples were extracted after decapitation. Half of the left lobe was frozen immediately on dry ice, and another half was fixed for histology, and liver sections were performed at 5 μm. All samples were stored at −80 °C for subsequent Western Blot or ELISA analyses. Liver histopathology Liver tissues designated for histopathological analysis were removed and immediately transferred to a 4 % formaldehyde solution (Sigma-Aldrich, Milwaukee, WI) and fixed for 24 h. Subsequently, the liver tissues were transferred to 70% ethanol for storage. The samples were embedded in paraffin; thin sections were cut and stained with Haematoxylin/Eosin. Stained sections were mounted with mounting medium. Images were taken using an Olympus VS120 Slide Scanner. Western blot analysis To analyze protein expression in both cytoplasmic and nuclear fractions, tissues were fractionated using established protocol [5,26,28,29]. NAc and/or liver samples were homogenized in buffer A (10 mM HEPES-KOH, pH 7.9; 1.5 mM MgCl2; 10 mM KCl; 1 mM Dithiothreitol (DDT); 1 mM phenylmethylsulfonyl fluoride (PMSF); 10 μL of protease inhibitor cocktail/ml of buffer A). The homogenized NAc samples or liver samples were incubated at 4 °C for 10 min prior to adding Nonidet P40 (NP40) to a final concentration of 0.1%. The NAc samples were then incubated for 2 min at 4 °C and centrifuged at 13,200 rpm for 15 min at 4 °C. The supernatant was removed, to obtain the cytosolic fraction, which contains also cell membrane proteins. NaF, Na-vanadate, and Na-pyrophosphate were added to the final concentration of 50, 10, and 0.1 mM, respectively. The pellet was resuspended in buffer B (20 mM HEPES-KOH, pH 7.9; 25% glycerol; 420 mM NaCl; 1.5 mM MgCl2; 1 mM DDT; 1 mM PMSF; 0.2 mM EDTA; 50 mM NaF; 10 mM Na vanadate; 0.1 mM Na pyrophosphate; 10 μL of protease inhibitor cocktail/ml of buffer B) and incubated for 30 min at 4 °C. The samples were then centrifuged at 13,200 rpm at 4 °C, and the supernatant was collected as the nuclear fraction. Protein concentration was determined with a detergent-compatible protein assay (Bio-Rad, Hercules, CA, USA), using bovine serum albumin as the standard. Proteins (10 μg per lane) were separated using 10% SDS-PAGE. The separated proteins were then transferred onto polyvinylidene difluoride (PVDF) membranes. Subsequently, the PVDF membranes were blocked with 5% fat-free milk in Tris-buffered saline with Tween 20 (TBST) at room temperature for 30 min. Membranes were incubated overnight at 4 °C with primary antibodies: rabbit anti-GLT-1 (1:1000; Abcam; Ab205248), rabbit anti-xCT (1:1000; Abcam; Ab175186), rabbit anti-mTOR (1:1000; Cell Signaling Technology, Inc.; 7C10), rabbit anti-Phospho-Akt (1:1000; Cell Signaling Technology, Inc.; D9E)), rabbit anti-Akt (1:1000; Cell Signaling Technology, Inc.; C67E7), rabbit anti-IKB-α (1:1000; Cell Signaling Technology, Inc.; L35A5)), rabbit anti-NFKB (1:1000; HUABIO; ER0815). Rabbit anti-GAPDH (1:1000; Cell Signaling Technology, Inc.; D16H11) and rabbit anti-LAMIN (1:1000; HUABIO; ET1606-27) were used as a control loading protein. Membranes were then washed on the next day for five times with TBST and then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (1; 4000) for 1 h at room temperature. Subsequently, the membranes were washed with TBST, dried with paper towels, and incubated with chemiluminescent reagents (Super Signal West Pico, Perce Inc., Appleton WI, USA). Digitized blot images were developed using the ChemiDoc imaging system (Bio-rad Laboratories). Each animal contributed one independent biological sample per protein. All samples for a given protein were run on the same membrane whenever feasible. Densitometry was performed using ImageJ (Version 1.53t 24), and full uncropped blots are provided in the supplemental figure. Protein expression was normalized to the expression of the loading control protein, GAPDH for cytoplasmic proteins. For phosphorylated Akt expression, total Akt was used as a control; for nuclear fraction NFKB expression, LAMIN was used as a control for nuclear proteins. For each protein, one biological sample per animal was loaded, and thus n reflects the number of animals per group (n = 5–6). Each Western blot represents an independent biological replicate set, with no animal sampled more than once. All proteins were measured using single-run membranes whenever possible. When multiple proteins required analysis on the same membrane, blots were cut horizontally to probe individual targets. When stripping and reprobing were necessary, membranes were incubated in Restore™ stripping buffer (ThermoFisher), reblocked, and reprobed using standard procedures. Only blots with complete stripping (verified by absence of HRP signal) were quantified. For proteins requiring separate membranes, each membrane contained all experimental groups (saline, hydrocodone, and MC-100093/MC-290401/MC-290013 groups). No representative images in the Figures were generated by splicing lanes from different membranes. If a protein required analysis on more than one membrane due to lane capacity, this is noted in the Figure legends, and densitometry was normalized within each membrane to the same control group. ELISA assay ELISA kits (R&D Systems) were used to measure TNF-α, IL-1 beta, and IL-6 levels in mouse liver homogenates according to the manufacturer’s protocols. Each set of experiments was performed duplicate and normalized to total protein (pg/mg). Concentrations of cytokines were quantified using commercially available ELISA kits and expressed as absolute values normalized to total protein. Individual biological replicates were plotted to illustrate data distribution. Liver histopathology Liver tissue was fixed in 4% formaldehyde, embedded, sectioned and stained with H&E. Liver inflammation was identified qualitatively. Data analyses GraphPad Prism (version 10.1.2) was used to analyze Western blot and ELISA data. The data from Western blot studies for p-Akt/Akt, NFKB/LAMIN, GLT-1/GAPDH, xCT/GAPDH, NFKB/GAPDH, mTOR/GAPDH, and IKB-α/GAPDH expression are presented as % of the control and analyzed using one-way ANOVA followed by Tukey’s post hoc test. All Western blot results are expressed as means ± S.E.M. ELISA data were analyzed using a one-way ANOVA for each protein or cytokine followed by Tukey’s post hoc test. Biological replicates were defined as individual animals (n = 5–7/group), where each animal contributes one independent sample. The difference between treatment groups was considered significant at p < 0.05, and data were presented as mean ± S.E.M. Results Effects of MC-100093, MC-290013, and MC-290401 treatments in GLT-1 and xCT expression in the NAc Previous work from our laboratory demonstrated that chronic hydrocodone exposure significantly reduced GLT-1 and xCT expression in the mesocorticolimbic brain regions. Beta-lactams have been shown to protect against neurotoxicity induced by the downregulation of GLT-1 and xCT with chronic exposure to drugs of abuse such as hydrocodone, morphine, and fentanyl [3,14,15]. Building on this observation, we sought to determine whether the novel synthetic non-antibiotic beta-lactam compounds, MC-100093 and MC-290401, and non-beta-lactam compound, MC-290013, could alleviate the hydrocodone-induced downregulation of GLT-1 and xCT expression in the cytoplasmic fraction of the NAc. We assigned mice to five treatment groups: saline + saline, hydrocodone + saline, hydrocodone + MC-100093, hydrocodone + MC-290013, and hydrocodone + MC-290401 groups. We observed significant differences in GLT-1 (F3,16 = 7.769, p < 0.001, n = 6/group) (Fig. 1A) and xCT (F3,16 = 6.905, p < 0.0001, n = 6/group) (Fig. 1B) protein expression in the NAc among all tested groups. Tukey’s multiple comparisons test showed that hydrocodone-induced decrease in GLT-1 expression was attenuated with seven days post-treatment of MC-100093 (p < 0.05), MC-290013 (p < 0.01), and MC290401 (p < 0.05) (Fig. 1A). GLT-1 expression in the hydrocodone group was downregulated by 42.21% of control (57.79 ± 8.95). Treatment with MC-100093, MC-290013, and MC-290401 upregulated GLT-1 expression by 60.8%, 73.7%, and 57.8%, respectively, relative to hydrocodone group, corresponding to 92.92 ± 8.3, 100.4 ± 7.8, and 91.2 ± 3.2 of control group. In addition, Tukey’s multiple comparisons test revealed that treatments with MC-100093 (p < 0.01), MC-290013 (p < 0.001), and MC-290401 (p < 0.01) attenuated hydrocodone-induced downregulation in xCT expression (Fig. 1B). xCT expression in the hydrocodone group was downregulated by 31.22 % of control (68.78 ± 7.48). Treatment with MC-100093, MC-290013, and MC-290401 upregulated xCT expression by 61.4%, 81.0%, and 63.7%, respectively, relative to hydrocodone group, corresponding to 111.0 ± 6.39, 124.5 ± 8.58, and 112.5 ± 8.84 of control. These findings demonstrate that hydrocodone decreases intracellular GLT-1 and xCT, while treatment with MC compounds partially normalizes this disruption. Effects of chronic hydrocodone exposure, MC-100093, MC-290013, or MC-290401 treatment on GLT-1 and xCT expression in NAc. (A) Representative Western blot images for GLT-1 expression of the cytoplasmic fraction in NAc. One-way ANOVA followed by Tukey’s post hoc test revealed a significant decrease in the ratio of GLT-1/GAPDH in the hydrocodone-treated group compared to the control group. Treatments with MC-100093 (100 mg/kg), MC-290013 (100 mg/kg), and MC-290401 (100 mg/kg) attenuated hydrocodone-induced downregulation of GLT-1 expression. (B) Representative Western blot images for xCT expression of the cytoplasmic fraction in NAc. One-way ANOVA followed by Tukey’s multiple comparisons revealed a significant downregulation in the ratio of xCT/GAPDH in the hydrocodone-treated group compared to the control group. Treatments with MC-100093 (100 mg/kg), MC-290013 (100 mg/kg), and MC-290401 (100 mg/kg) increased the hydrocodone-induced downregulation in xCT expression as compared to the hydrocodone-treated group. Control group data were represented as 100%. The values are expressed as means ± S.E.M. (∗p < 0.05, ∗∗p < 0.01). Control (n = 6), Hydrocodone (n = 6), Hydrocodone-MC-100093 (n = 6), Hydrocodone-MC-290013 (n = 6), and Hydrocodone-MC290401 (n = 6) groups. GLT-1, glutamate transporter 1; xCT, cystine/glutamate antiporter; NAc, nucleus accumbens. Data represent (n = 6 biological replicates per group) with each animal contributing one independent tissue sample. Representative images were derived from Western blot membranes containing all treatment groups analyzed together. Effects of chronic hydrocodone exposure, MC-100093, MC-290013, or MC-290401 treatments on mTOR and Akt expression in the NAc Next, we determined the molecular mechanism of action of MC-100093, MC-290013, and MC-290401 for the upregulation of GLT-1 in the NAc. It has been shown that the mammalian target of rapamycin (mTOR) and protein kinase B (Akt) are involved in the regulation of GLT-1 expression [30]. According to the above findings, we determined whether the novel synthetic GLT-1 modulators (MC-100093, MC-290401 and MC-290013) upregulated the expression of GLT-1 by modulating the expression of mTOR and Akt. Hydrocodone significantly increased cytoplasmic mTOR expression and decreased phosphorylated Akt (p-AKT/AKT) ratios. One-way ANOVA analyses revealed a significant main effect among all treated groups in mTOR (F3,20 = 9.495, p < 0.001, n = 6/group, Fig. 2A) and Akt (F3,20 = 14.08, p < 0.0001, n = 6/group, Fig. 2B). Tukey’s multiple comparisons tests showed that hydrocodone-induced increase in mTOR was alleviated with MC-100093 (p < 0.001), MC-290013 (p < 0.01), and MC-290401 (p < 0.01) treatments (Fig. 2A). mTOR expression in the hydrocodone group was upregulated by 25.8 % of control (125.8 ± 6.7). Treatment with MC-100093, MC-290013, and MC-290401 downregulated mTOR expression by 29.8%, 28.2%, and 22.5%, respectively, relative to hydrocodone group, corresponding to 88.30 ± 3.88, 90.35 ± 6.27, and 97.51 ± 5.28 of control group. Furthermore, post hoc test also demonstrated significant increase in the Akt expression in the MC-100093 (p < 0.001), MC-290013 (p < 0.001), and MC-290401 (p < 0.001) treated groups as compared to the hydrocodone-treated group (Fig. 2B). Akt expression in the hydrocodone group was downregulated by 33.66% of control group (66.34 ± 5.506). Treatment with MC-100093, MC-290013, and MC-290401 upregulated Akt expression by 57.2%, 60.1%, and 61.3%, respectively, relative to hydrocodone group, corresponding to 104.3 ± 4.75, 106.2 ± 5.79, and 107.0 ± 4.95 of control group. These effects suggest that hydrocodone disrupts signaling pathways associated with GLT-1 transcription and treatment with GLT-1 enhancers normalized these expression patterns. Effects of chronic hydrocodone exposure, MC-100093, MC-290013, or MC-290401 treatment on mTOR and Akt expression in NAc. (A) Representative Western blot images for mTOR expression of the cytoplasmic fraction in NAc. One-way ANOVA followed by Tukey’s multiple comparisons revealed a significant increase in the ratio of mTOR/GAPDH in the hydrocodone-treated group compared to the control group. Treatments with MC-100093 (100 mg/kg), MC-290013 (100 mg/kg), and MC-290401 (100 mg/kg) reduced the hydrocodone-induced upregulation in mTOR expression as compared to the hydrocodone-treated group. (B) Representative Western blot images for Akt expression of the cytoplasmic fraction in NAc. One-way ANOVA followed by Tukey’s post hoc test revealed a significant decrease in the ratio of p-Akt/Akt in the hydrocodone-treated group compared to the control group. Treatments with MC-100093 (100 mg/kg), MC-290013 (100 mg/kg), and MC-290401 (100 mg/kg) increased the hydrocodone-induced downregulation in Akt expression as compared to the hydrocodone-treated group. Control group data were represented as 100%. The values are expressed as means ± S.E.M. (∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). Control (n = 6), Hydrocodone (n = 6), Hydrocodone-MC-100093 (n = 6), Hydrocodone-MC-290013 (n = 6), and Hydrocodone-MC290401 (n = 6). Akt, protein kinase B; mTOR, mammalian target of rapamycin; NAc, nucleus accumbens. Data represent (n = 6 biological replicates per group) with each animal contributing one independent tissue sample. Representative images were derived from Western blot membranes containing all treatment groups analyzed together. Effects of chronic hydrocodone exposure, MC-100093, MC-290013, and MC-290401 treatments on NFκB and IKB-α expression in the NAc We further explored the expression of target proteins, which are suggested to be involved in GLT-1 upregulation by examining the effects of these GLT-1 modulators on the expression of NF-κB in the cytoplasmic fraction and NF-κB in the nuclear fraction, as well as IkB-α in the cytoplasmic fraction in the NAc. One-way ANOVA analyses demonstrated a significant effect on the protein expression of NF-κB in the cytoplasmic fraction (F3,20 = 9.257, p < 0.0001, n = 6/group, Fig. 3A), NF-κB in the nuclear fraction (F3,20 = 11.09, p < 0.001, n = 6/group, Fig. 3B), and IKB-α (F3,19 = 7.820, p < 0.01, n = 6/group, Fig. 3C). Tukey’s multiple comparisons test indicated that the hydrocodone-induced decrease in NF-κB expression in the cytoplasmic fraction was attenuated by MC-100093 (p < 0.01), MC-290013 (p < 0.001), and MC-290401 (p < 0.05) treatments (Fig. 3A). NF-κB (cytoplasmic fraction) expression in the hydrocodone group was downregulated by 14.71% of control group (85.29 ± 4.67). Treatment with MC-100093, MC-290013, and MC-290401 upregulated NF-κB (cytoplasmic fraction) expression by 29.2%, 36.8%, and 25.7%, respectively, relative to hydrocodone group, corresponding to 110.2 ± 5.05, 116.7 ± 4.81, and 107.2 ± 3.13 of control group. Similarly, the hydrocodone-induced decrease in the expression of NF-κB in the nuclear fraction was also attenuated by treatments of MC-100093 (p < 0.001), MC-290013 (p < 0.01), and MC-290401 (p < 0.001) (Fig. 3B). NF-κB (nuclear fraction) expression in the hydrocodone group was downregulated by 27.75% of control group (72.25 ± 3.41). Treatment with MC-100093, MC-290013, and MC-290401 upregulated NF-κB (nuclear fraction) expression by 42.0%, 40.1%, and 43.3%, respectively, relative to hydrocodone group, corresponding to 102.7 ± 4.78, 101.3 ± 4.01, and (103.7 ± 5.70) of control group. In addition, treatments with MC-100093 (p < 0.01), MC-290013 (p < 0.01), and MC-290401 (p < 0.05) normalized hydrocodone-induced upregulation in IKB-α in the NAc (Fig. 3C). IKB-α expression in the hydrocodone group was upregulated by 84.1% of control group (184.1 ± 18.81). Treatment with MC-100093, MC-290013, and MC-290401 downregulated IKB-α expression by 54.3%, 46.3%, and 36.8%, respectively, relative to hydrocodone group, corresponding to 83.97 ± 15.96, 98.77 ± 14.57, and 116.2 ± 13.67 of control group. Effects of chronic hydrocodone exposure, MC-100093, MC-290013, or MC-290401 treatment on NFκB and IKB-α expression in NAc. (A) Representative Western blot images for NFκB expression of the cytoplasmic fraction in NAc. One-way ANOVA followed by Tukey’s post hoc test revealed a significant downregulation in the ratio of NFκB/GAPDH in the hydrocodone-treated group compared to the control group. Treatments with MC-100093 (100 mg/kg), MC-290013 (100 mg/kg), and MC-290401 (100 mg/kg) attenuated hydrocodone-induced reduction in NFκB expression. (B) Representative Western blot images for NFκB expression of the nuclear fraction in NAc. One-way ANOVA followed by Tukey’s post hoc test revealed a significant downregulation in the ratio of NFκB/Lamin in the hydrocodone-treated group compared to the control group. Treatments with MC-100093 (100 mg/kg), MC-290013 (100 mg/kg), and MC-290401 (100 mg/kg) attenuated hydrocodone-induced reduction in NFκB expression. (C) Representative Western blot images for IKB-α expression of the cytoplasmic fraction in NAc. One-way ANOVA followed by Tukey’s post hoc test revealed a significant upregulation in the ratio of IKB-α/GAPDH in the hydrocodone-treated group compared to the control group. Treatments with MC-100093 (100 mg/kg), MC-290013 (100 mg/kg), and MC-290401 (100 mg/kg) attenuated hydrocodone-induced upregulation in IKB-α expression. Control group data were represented as 100%. The values are expressed as means ± S.E.M. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Control (n = 6), Hydrocodone (n = 6), Hydrocodone-MC-100093 (n = 6), Hydrocodone-MC-290013 (n = 6), and Hydrocodone-MC290401 (n = 6). NFκB, Nuclear factor kappa-light-chain-enhancer of activated B cells; IKB-α, NF-kappa-B inhibitor alpha; NAc, nucleus accumbens. Data represent (n = 6 biological replicates per group) with each animal contributing one independent tissue sample. Representative images were derived from Western blot membranes containing all treatment groups analyzed together. Effects of chronic hydrocodone exposure and MC-100093, MC-290013, or MC-290401 treatments in the liver using histopathological inflammatory identification After 14 days of chronic exposure to hydrocodone, liver samples were collected for H&E staining. As shown in Fig. 4, H&E labeling indicated that the liver of mice in the chronic hydrocodone exposure group (Fig. 4A) possessed mixed inflammatory cell infiltration (predominantly neutrophils and lymphocytes) around the central veins as compared to the control group (Fig. 4B). Post-treatments with MC-100093 (Fig. 4C), MC-290013 (Fig. 4D), or MC-290401 (Fig. 4E) qualitatively reduced inflammatory infiltration in hydrocodone treated mice compared to vehicle control group. Absolute quantification of neutrophils was not performed, as the available tissue sections and staining conditions were not optimized for reliable cell-type–specific counting. (A) The liver section showed a central vein with surrounding unremarkable hepatocytes in the control group. (B) A section of the liver obtained from the hydrocodone-treated group showed inflammation around the central vein. (C) and (D) liver sections showed limited inflammation around the central vein in the hydrocodone-MC-100093-treated and hydrocodone-MC290013-treated groups. (E) Liver tissues showing mild inflammation around the central vein for the hydrocodone-MC290401 treated group. The red arrow indicates inflammation. H&E stain x 100. CV, central vein. Effects of chronic hydrocodone exposure, MC-100093, MC-290013, or MC-290401 treatments on GLT-1 and xCT expression in the liver The relative protein expression was detected using Western Blot testing to further assess the effects of MC-100093, MC-290013, or MC-290401 on the expression of GLT-1 and xCT in the liver. Unlike the NAc, the outcomes revealed that xCT (F3,16 = 11.77, p < 0.001, n = 5/group, Fig. 5A) and GLT-1 (F3,16 = 6.290, p < 0.01, n = 5/group, Fig. 5B) were significantly increased in the hydrocodone-treated group related to the control group, whereas MC-100093 (p < 0.001, Fig. 5A; p < 0.05, Fig. 5B), MC-290013 (p < 0.01, Fig. 5B; p < 0.05, Fig. 5B), or MC-290401 (p < 0.001, Fig. 5A; p < 0.01, Fig. 5B) treatments suppressed this outcome for GLT-1 and xCT, respectively. The expression of xCT in the liver of the hydrocodone group was upregulated by 65.4% of control (165.4 ± 11.06). Treatment with MC-100093, MC-290013, and MC-290401 downregulated xCT expression by 33.4%, 25.4%, and 35.9%, respectively, relative to hydrocodone group, corresponding to 110.1 ± 4.91, 123.4 ± 9.24, and 106.0 ± 4.32 of control. Moreover, the expression of GLT-1 in the liver of the hydrocodone group was upregulated by 66.8% of control (166.8 ± 6.67). Treatment with MC-100093, MC-290013, and MC-290401 downregulated GLT-1 expression by 26.4%, 23.6%, and 31.8%, respectively, relative to hydrocodone group, corresponding to 122.7 ± 12.44, 127.4 ± 11.49, and 113.7 ± 4.33 of control group. Effects of chronic hydrocodone exposure, MC-100093, MC-290013, or MC-290401 treatments on GLT-1 and xCT expression in liver. (A) Representative Western blot images for GLT-1 expression in the liver. One-way ANOVA followed by Tukey’s post hoc test revealed a significant increase in the ratio of GLT-1/GAPDH in the hydrocodone-treated group compared to the control group. Treatments with MC-100093 (100 mg/kg), MC-290013 (100 mg/kg), and MC-290401 (100 mg/kg) attenuated hydrocodone-induced increase in GLT-1 expression. (B) Representative Western blot images for xCT expression in the liver. One-way ANOVA followed by Tukey’s multiple comparisons revealed a significant upregulation in the ratio of xCT/GAPDH in the hydrocodone-treated group compared to the control group. Treatments with MC-100093 (100 mg/kg), MC-290013 (100 mg/kg), and MC-290401 (100 mg/kg) attenuated hydrocodone-induced increase in xCT expression. Control group data were represented as 100%. The values are expressed as means ± S.E.M. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Control (n = 5), Hydrocodone (n = 5), Hydrocodone-MC-100093 (n = 5), Hydrocodone-MC-290013 (n = 5), and Hydrocodone-MC290401 (n = 5). GLT-1, glutamate transporter 1; xCT, cystine/glutamate antiporter. Data represent each animal contributing one independent tissue sample (n = 5 biological replicates per group). Representative images were derived from membranes containing all treatment groups analyzed together. Effects of chronic hydrocodone exposure, MC-100093, MC-290013, or MC-290401 treatments on TNF-α, IL-1β, and IL-6 levels in the liver To determine the effects of MC-100093, MC-290013, or MC-290401 treatments on proinflammatory mediators produced in the liver, we examined the expression of TNF-α, IL-1β, and IL-6 following chronic hydrocodone exposure. There was a significant difference in TNF-α (F4,30 = 18.36, p < 0.0001, n = 6-7/group), IL-1β (F4,23 = 12.51, p < 0.0001, n = 6-7/group), and IL-6 (F4,34 = 6.269, p < 0.001, n = 6-7/group) (Fig. 6A, B, C respectively). One-way ANOVA indicated that chronic hydrocodone exposure increased TNF-α (p < 0.0001, Fig. 6A), IL-1β (p < 0.0001, Fig. 6B), and IL-6 (p < 0.01, Fig. 6C) levels in the liver. Post hoc test for multiple comparisons revealed that MC-100093, MC-290013 and MC-290401 treatments significantly attenuated hydrocodone-induced increase in TNF-α, IL-1β, and IL-6 cytokine levels in the liver. TNF-α level in the hydrocodone group was increased by 175.25% of saline treated group (269.2 ± 17.93). Treatments with MC-100093, MC-290013, and MC-290401 decreased TNF-α level by 45.1%, 26.8%, and 24.9%, respectively, relative to hydrocodone group, corresponding to 147.6 ± 6.53, 197.0 ± 11.70, and 202.1 ± 22.42 of saline treated group. Additionally, IL-1β level in the hydrocodone group increased by 146.1% of saline treated group (234.2 ± 26.40). Treatments with MC-100093, MC-290013, and MC-290401 decreased IL-1β level by 45.9%, 32.8%, and 43.3%, respectively, relative to hydrocodone group, corresponding to 126.5 ± 6.49, 157.2 ± 6.61, and 141.9 ± 16.67 of saline treated group. Moreover, IL-6 level in the hydrocodone group increased by 80.25% of saline treated group (234.2 ± 26.40). Treatments with MC-100093, MC-290013, and MC-290401 decreased IL-6 level by 46.0%, 38.9%, and 32.7%, respectively, relative to hydrocodone group, corresponding to 565.9 ± 61.05, 640.0 ± 49.66, and 704.3 ± 90.91 of saline treated group. ELISA results are presented as absolute concentrations of cytokines (pg/mg total protein), with individual biological data shown for each animal. Effects of chronic hydrocodone exposure, MC-100093, MC-290013, or MC-290401 treatments on TNF-α, IL-1β, and IL-6 levels in the liver tissues. Chronic hydrocodone exposure increased TNF-α (A), IL-1β (B), and IL-6 (C) levels in the liver compared to the control. Treatments with MC-100093 (100 mg/kg), MC-290013 (100 mg/kg), and MC-290401 (100 mg/kg) decreased the levels of TNF-α (A), IL-1β (B), and IL-6 (C) in the liver. Data are expressed as means ± S.E.M. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). Control, Hydrocodone (n = 6–7), Hydrocodone-MC-100093 (n = 6–7), Hydrocodone-MC-290013 (n = 6–7), and Hydrocodone-MC290401 (n = 6–7). TNF-α, tumor necrosis factor-alpha; IL-1β, interleukin-1 beta; IL-6, interleukin-6. Discussion The results demonstrated for the first time that non-antibiotic beta-lactam compounds, MC-290401, and non-beta-lactam, MC-290013, upregulate GLT-1 expression in the NAc of male mice. This study confirmed the GLT-1 modulatory effect of MC-100093 in this mouse model of chronic hydrocodone exposure. In addition, the non-antibiotic beta-lactams, MC-100093 and MC-290401, and non-beta-lactam, MC-290013, alleviated the hydrocodone-induced decrease in xCT expression and the hydrocodone-induced increase in IKB-α expression in the NAc. In addition, MC-100093, MC-290401, and MC-290013 treatments reversed the hydrocodone-induced increase in the levels of GLT-1, xCT, and the inflammatory mediators, TNF-α, IL-1β, and IL-6, in the liver. To the best of our knowledge, this study reports for the first time the effects of chronic hydrocodone exposure on GLT-1 and xCT expression as well as inflammatory factors (TNF-α, IL-1β, and IL-6) in the liver of male mice. It is well known that GLT-1 is colocalized with xCT in astrocytes and regulates basal extracellular glutamate concentrations in the brain [[31], [32], [33]]. Regarding the detection of GLT-1 expression, it is important to note that GLT-1 is known to form homomultimeric complexes, and Western blot analysis commonly reveals not only the monomeric band at ∼65 kDa but also higher molecular weight bands corresponding to multimers (∼140 and ∼210 kDa) as described in previous study [34]. These higher molecular weight bands represent multimeric forms of GLT-1 rather than distinct isoforms. In the present study, the ∼65 kDa monomer band was used for densitometric analysis as this monomer is the most common and standard band quantified to measure total GLT-1 protein expression as discussed previously [35]. Extensive studies from our laboratory and others have established the expression of the GLT-1 monomer as the standard target protein for quantifying total GLT-1 expression and conducting statistical comparisons between control and experimental groups [3,6,[10], [11], [12], [13],28,[36], [37], [38]]. Accordingly, we analyzed the GLT-1 monomer in this study to determine the differential changes between the control and treated groups. An important limitation of this analysis is that GLT-1 was quantified at the monomeric level without directly assessing its oligomeric or multimeric state. GLT-1 is known to form oligomeric assemblies, with trimers being a well-established structural state, although individual transporter protomers contain independent substrate translocation pathways. Consequently, measurement of the monomeric GLT-1 band provides an estimate of protein abundance but does not necessarily reflect the amount of GLT-1 present as assembled transporter complexes. Studies are warranted to quantify and analyze the expression of multimers of GLT-1 between control and experimental groups. Several preclinical studies have shown that chronic exposure to opioids such as hydrocodone, morphine, oxycodone, and cocaine can lead to dysregulation of glutamate homeostasis in mesocorticolimbic brain regions, an effect associated with downregulation of GLT-1 and xCT expression [3,14,[39], [40], [41]]. Consistent with these reports, downregulation of GLT-1 and xCT expression were observed in the NAc of mice chronically exposed to hydrocodone, and treatments with MC-100093, MC-290013, and MC-290401 alleviated hydrocodone-induced downregulation of GLT-1 and xCT expression. Our results expand past reports of MC-100093 efficacy and provide the first opioid-related evaluation of MC-290401 and MC-290013. The present findings suggest that these GLT-1 modulators have the potential to mitigate the effects of chronic hydrocodone exposure by restoring GLT-1 and xCT levels in the NAc, thereby preventing neurotoxicity caused by excessive extracellular glutamate levels. It is important to note that there is a large body of evidence that beta-lactam antibiotic, ceftriaxone, is unable to upregulate GLT-1 in healthy rodents [42]; as the case in earlier published studies investigating the effect of MC-100093 on attenuating cocaine relapse in rats [13]. Note that beta-lactams non-antibiotics (MC-100093 and MC-290401) are derived from ceftriaxone. Thus, we did not test MC-100093 for its ability to increase GLT-1 protein expression in the hydrocodone-naïve rats. This will be addressed in future study by our laboratory. It has been reported that the beta-lactam-based GLT-1 enhancer, ceftriaxone, stimulates the upregulation of GLT-1 through the NF-κB pathway [29] as summarized in Fig. 7. Furthermore, it has been previously demonstrated that the mTOR and Akt signaling pathway, as an upstream of NF-κB, is involved in the upregulation of GLT-1 expression [28,30,43] (Fig. 7). Therefore, in the present study, we explored the expression of GLT-1 and xCT alongside the expression of target proteins of the mTOR/Akt/NF-κB pathway. mTOR interacts with Raptor and Rictor to form two structurally and functionally distinct signaling complexes: mTORC1 and mTORC2 [44,45]. mTORC1 is mainly involved in cell growth and energy metabolism, while mTORC2 is involved in cell survival and Akt activation [46]. Several reports have demonstrated that inhibition of mTORC1 can lead to activation of mTORC2, which in turn phosphorylates Akt [[47], [48], [49], [50]]. Previous evidence suggested that morphine exposure stimulates the activation of mTORC1 [51,52]. These findings are consistent with our present findings, indicating that mTOR is upregulated in the NAc after chronic hydrocodone exposure. Importantly, hydrocodone-induced mTOR upregulation was attenuated by MC-100093, MC-290401, and MC-290013 treatments. The current findings suggest that hydrocodone increases the expression of mTORC1; however, future studies are required to validate this notion by examining the expression of Raptor and Rictor. This schematic is presented as a conceptual model illustrating potential signaling pathways previously shown to be associated with GLT-1 regulation. It does not represent experimentally demonstrated mechanisms from the present study. We further investigated the Akt signaling pathway in the NAc, as recent studies have shown that Akt activation is involved in the upregulation of GLT-1 expression [53]. We found that p-Akt was downregulated in the NAc after chronic hydrocodone exposure compared to the controls. This is consistent with previous findings indicating the downregulation of p-Akt expression after exposure to morphine, oxycodone, and hydrocodone [54,55]. More importantly, our results showed that p-Akt expression was upregulated after MC-100093, MC-290401, and MC-290013 treatments. Similarly, previous study from our laboratory has demonstrated that ceftriaxone attenuated hydrocodone-induced downregulation of GLT-1 by activating p-Akt in mesocorticolimbic brain regions [3], suggesting that beta-lactam compounds have the ability to enhance GLT-1 expression. We propose here that treatments with the non-antibiotic beta-lactams, MC-100093 or MC-290401, and the non-beta-lactam compound, MC290013, upregulates GLT-1 expression in the NAc by reducing the expression of mTORC1 and subsequently increasing the expression of Akt. Further studies are warranted to determine the mechanistic involving the association between GLT-1 and mTORC1 and Akt, using mTORC1 and Akt inhibitors. This study further explored the downstream signaling of Akt activation, as Akt has been reported to activate NF-κB [56]. Several studies have demonstrated the involvement of NF-κB in regulating GLT-1 expression, depending on the drug administered [29,57]. Indeed, it was found that Akt-induced activation of the NFκB signaling cascade required degradation of IkB-α, allowing NFκB to translocate to the nucleus, where it induces transcription of target genes [58]. Consistent with these reports, we found that chronic administration of hydrocodone decreased the expression of NFκB in both the cytoplasmic and nuclear fractions of the NAc, and this downregulation was attenuated by MC-100093, MC-290401, and MC-290013 treatments. Furthermore, we found upregulation of IKB-α in the NAc of the hydrocodone-exposed group compared to the control group. Notably, downregulation of IKB-α was observed with treatment with MC-100093, MC-290401, and MC-290013, corresponding to the increase in NFκB expression in both cytoplasmic and nuclear fractions. This suggests that MC-100093, MC-290401 and MC290013 induce upregulation of NFκB in the cytoplasmic and nuclear fractions by activating the degradation of IKB-α. Hydrocodone altered the expression of mTOR, Akt, NFκB, and IκB-α, and treatment with MC-100093, MC-290401, and MC-290013 normalized these effects. These results are consistent with the involvement of signaling component known to regulate GLT-1 expression. To the best of our knowledge, this is the first experimental study to investigate the effects of chronic exposure to hydrocodone administration in the liver of mice. When the liver injury occurs, inflammatory cells including lymphocytes migrate to the liver and initiate an inflammatory response [59]. This is consistent with our results that histopathological examination of liver tissues in the hydrocodone-exposed group showed lymphocytic infiltration around the portal vein compared with the saline-treated group, whereas liver tissues of MC-100093, MC-290401, and MC-290013 showed reduced hepatocyte inflammatory response compared with the hydrocodone-treated group. It is well known that chronic exposure to morphine induced the production of reactive oxygen species (ROS) in the liver [16,60]. Overproduction of ROS in the liver can lead to increased release of proinflammatory cytokines and this has been shown to be associated with activation of the NF-κB pathway [61]. This latter study found that chronic exposure to hydrocodone increased hepatic proinflammatory cytokines (TNF-α, IL-1β, and IL-6), accompanied by inflammatory cell infiltration. Importantly, MC-100093, MC-290401, and MC-290013 treatments significantly suppressed the elevation of proinflammatory cytokines in the liver, indicating potential anti-inflammatory properties, and these effects might be mediated through modulation of GLT-1 expression in the liver. Although it is well known that GLT-1 regulates the uptake of glutamate in the brain, the function of hepatic GLT-1 is unclear. However, studies suggested that perivenous cells of the liver express high levels of glutamine synthetase colocalized with GLT-1; the import of extracellular glutamate by GLT-1 into hepatocytes are converted to glutamine by glutamine synthetase to some extent reducing excess of ammonia [62,63]. The liver contains a high glutathione (GSH) level, which plays a vital role in effectively scavenging ROS during liver injury [64]. In hepatic cells, xCT/SLC7A11-mediated cystine uptake promotes glutathione biosynthesis and protects hepatocytes against ROS [65,66]. Our data suggest that chronic hydrocodone exposure increases ROS in the liver, leading to cysteine deficiency and GSH depletion, which triggers compensatory upregulation of xCT in hepatic cells. MC-100093, MC-290401, and MC-290013 treatments reversed the hydrocodone-induced upregulation in the expression of xCT in the liver. It is important to note that GLT-1 is the major glutamate transporter in the liver [24,67]. Previous evidence suggests that GLT-1 expression is upregulated in vitro and in vivo models of liver disease [68,69]. In contrast to our findings in the brain, GLT-1 expression was significantly upregulated in the liver after chronic hydrocodone exposure, suggesting tissue-specific adaptive responses rather than a uniform mechanism. Our results showed that MC-100093, MC-290401, and MC-290013 treatments attenuated hydrocodone-induced increase in GLT-1 expression in the liver. This is in line with the observation of recent study which indicated that beta-lactams (MC-100093 and ceftriaxone) modulate the changes in metabolomic profiles in the liver of a fentanyl overdose mouse model [17]. Note that immunocytochemistry for detection of GLT-1 might be probably better than Western blot technique as GLT-1 expression may vary in different parts of the liver. The above results demonstrate that non-antibiotic beta-lactams, MC-100093 and MC-290401, and the non-beta-lactam compound, MC290013, exert protective effects against hydrocodone-induced inflammation in the liver. GLT-1 and xCT in hepatic cells were measured in cytoplasmic fractions, while cytoplastic may reflect altered intracellular trafficking. Therefore, further studies are warranted to test the effect of MC-100093, MC-290401, and MC-290013 on oxidative stress markers, liver enzymes, and membrane localization fraction to characterize transporter trafficking more thoroughly in chronic hydrocodone-induced liver inflammation. Further studies are warranted to aim at investigating the molecular effects in the brain and liver as well as behavioral testing at different doses of MC-100093, MC-290401, and MC-290013. In addition, other studies are warranted to determine the impact of opioids on the glutamate-glutamine synthesis in association with ammonia. Conclusion Taken together, our results indicate that post-treatment with the non-antibiotic beta-lactams,MC-100093 and MC-290401, and the non-beta-lactam compound, MC290013, can restore hydrocodone-induced chronic downregulation of GLT-1 and xCT levels in the NAc. Our results confirmed that MC-100093, MC-290401, and MC-290013 treatments normalized the levels of GLT-1, Akt, NFκB, and mTOR expression. This signaling pathway is initiated by downregulating mTORC1 expression, increasing Akt activation and NFκB translocation to the nucleus, thereby increasing GLT-1 transcription. In addition, this study also showed that chronic exposure to hydrocodone can cause increases in neutrophils and inflammation in the liver. Treatments with MC-100093, MC290401, and MC-290013 attenuated hydrocodone-induced increases in neutrophils, hepatic glutamate transporters (GLT-1 and xCT) and inflammation factors (TNF-α, IL-1β, and IL-6) in the liver. Author contributions W·W.: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Investigation, & Data curation. M.A-G.: Resources & Funding acquisition. A.S.M.: Investigation & Methodology. W.C.: Resources & Methodology. Y.S.: Writing – review & editing, Visualization, Validation, Supervision, Project administration, Funding acquisition, & Conceptualization. Funding This research study was conducted in part with the support of Award Number AA029674 (Y.S.) from National Institutes on Alcohol Abuse and Alcoholism(NIAAA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Alcohol Abuse and Alcoholism or the National Institutes of Health (NIH). Declaration of interest statement The authors declare that they have no conflicts of interest. Acknowledgment The authors would like to thank Khokon Kanti Bhowmik for his help with the calculation of the percentage of changes in the expression of target proteins. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.neurot.2026.e01071. Supplementary data The following are the Supplementary data to this article. Multimedia component 1 Chemical structures of ceftriaxone (beta-lactam antibiotic), MC-100093 (beta-lactam non-antibiotic), MC-290401 (beta-lactam non-antibiotic), and MC-290013 (non-beta lactam). References Associated Data Supplementary Materials Multimedia component 1